Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (341-350 of 509) with videos related to

Pageof 51
Sort By:
Annals of Surgical Oncology|August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary CentersFulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma GroupNicolas Penel, Axel Le Cesne, Sylvie Bonvalot, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2020
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanibNicolas Penel, Olivier Mir, Jennifer Wallet, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
The Oncologist|December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
BMJ Open|June 21, 2019
ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocolAude Lacourt, Brice Amadéo, Céline Gramond, et al.
Translational Oncology|November 18, 2021
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER programPhilippe A Cassier, Clémentine Peyramaure, Valery Attignon, et al.
Gynecologic Oncology|July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Pageof 51

Showing results (341-350 of 509) with videos related to

Sort By:
Pageof 51
Annals of Surgical Oncology|August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary CentersFulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma GroupNicolas Penel, Axel Le Cesne, Sylvie Bonvalot, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2020
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanibNicolas Penel, Olivier Mir, Jennifer Wallet, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
The Oncologist|December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
BMJ Open|June 21, 2019
ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocolAude Lacourt, Brice Amadéo, Céline Gramond, et al.
Translational Oncology|November 18, 2021
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER programPhilippe A Cassier, Clémentine Peyramaure, Valery Attignon, et al.
Gynecologic Oncology|July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
Pageof 51